Literature DB >> 22791078

Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.

Jasper Stevens1, Bart A Ploeger, Margareta Hammarlund-Udenaes, Gunilla Osswald, Piet H van der Graaf, Meindert Danhof, Elizabeth C M de Lange.   

Abstract

The aim of this investigation was to develop a mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) model for the biological system prolactin response following a dopamine inhibition challenge using remoxipride as a paradigm compound. After assessment of baseline variation in prolactin concentrations, the prolactin response of remoxipride was measured following (1) single intravenous doses of 4, 8 and 16 mg/kg and (2) following double dosing of 3.8 mg/kg with different time intervals. The mechanistic PK-PD model consisted of: (i) a PK model for remoxipride concentrations in brain extracellular fluid; (ii) a pool model incorporating prolactin synthesis, storage in lactotrophs, release into- and elimination from plasma; (iii) a positive feedback component interconnecting prolactin plasma concentrations and prolactin synthesis; and (iv) a dopamine antagonism component interconnecting remoxipride brain extracellular fluid concentrations and stimulation of prolactin release. The most important findings were that the free brain concentration drives the prolactin release into plasma and that the positive feedback on prolactin synthesis in the lactotrophs, in contrast to the negative feedback in the previous models on the PK-PD correlation of remoxipride. An external validation was performed using a dataset obtained in rats following intranasal administration of 4, 8, or 16 mg/kg remoxipride. Following simulation of human remoxipride brain extracellular fluid concentrations, pharmacodynamic extrapolation from rat to humans was performed, using allometric scaling in combination with independent information on the values of biological system specific parameters as prior knowledge. The PK-PD model successfully predicted the system prolactin response in humans, indicating that positive feedback on prolactin synthesis and allometric scaling thereof could be a new feature in describing complex homeostatic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791078     DOI: 10.1007/s10928-012-9262-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  39 in total

1.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats.

Authors:  Klaas P Zuideveld; Piet H Van der Graaf; Donald Newgreen; Richard Thurlow; Nicola Petty; Paul Jordan; Lambertus A Peletier; Meindert Danhof
Journal:  J Pharmacol Exp Ther       Date:  2004-01-08       Impact factor: 4.030

2.  Effect of social isolation on 24-h pattern of stress hormones and leptin in rats.

Authors:  Mario Perelló; Fernando Chacon; Daniel P Cardinali; Ana I Esquifino; Eduardo Spinedi
Journal:  Life Sci       Date:  2005-11-11       Impact factor: 5.037

Review 3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Authors:  Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 4.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

Authors:  Meindert Danhof; Elizabeth C M de Lange; Oscar E Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

5.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

Review 6.  Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.

Authors:  J Gabrielsson; A R Green
Journal:  J Pharmacol Exp Ther       Date:  2009-09-24       Impact factor: 4.030

7.  Pars distalis cell quantification in normal adult male and female rats.

Authors:  M O Dada; G T Campbell; C A Blake
Journal:  J Endocrinol       Date:  1984-04       Impact factor: 4.286

8.  Disposition of remoxipride in different species. Species differences in metabolism.

Authors:  M Widman; L B Nilsson; B Bryske; J Lundström
Journal:  Arzneimittelforschung       Date:  1993-03

9.  Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.

Authors:  N Mohell; M Sällemark; S Rosqvist; A Malmberg; T Högberg; D M Jackson
Journal:  Eur J Pharmacol       Date:  1993-07-06       Impact factor: 4.432

10.  Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.

Authors:  L Farde; C von Bahr
Journal:  Acta Psychiatr Scand Suppl       Date:  1990
View more
  17 in total

1.  Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes.

Authors:  Dominik Lott; Andreas Krause; Christian A Seemayer; Daniel S Strasser; Jasper Dingemanse; Thorsten Lehr
Journal:  Pharm Res       Date:  2016-12-27       Impact factor: 4.200

Review 2.  Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans.

Authors:  Mitchel J R Ruigrok; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2015-02-19       Impact factor: 4.009

3.  Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.

Authors:  Willem J van den Brink; Yin C Wong; Berfin Gülave; Piet H van der Graaf; Elizatbeth C M de Lange
Journal:  AAPS J       Date:  2016-10-26       Impact factor: 4.009

4.  The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.

Authors:  Elizabeth Cm de Lange
Journal:  Fluids Barriers CNS       Date:  2013-02-22

5.  White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.

Authors:  G Vlasakakis; E Comets; A Keunecke; I Gueorguieva; P Magni; N Terranova; O Della Pasqua; E C de Lange; C Kloft
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-05-01

6.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

7.  Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study.

Authors:  S Bakshi; E C de Lange; P H van der Graaf; M Danhof; L A Peletier
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-07-20

8.  A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.

Authors:  Yumi Yamamoto; Pyry A Välitalo; Dirk-Jan van den Berg; Robin Hartman; Willem van den Brink; Yin Cheong Wong; Dymphy R Huntjens; Johannes H Proost; An Vermeulen; Walter Krauwinkel; Suruchi Bakshi; Vincent Aranzana-Climent; Sandrine Marchand; Claire Dahyot-Fizelier; William Couet; Meindert Danhof; Johan G C van Hasselt; Elizabeth C M de Lange
Journal:  Pharm Res       Date:  2016-11-18       Impact factor: 4.200

9.  Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats.

Authors:  Amit Taneja; An Vermeulen; Dymphy R H Huntjens; Meindert Danhof; Elizabeth C M De Lange; Johannes H Proost
Journal:  Data Brief       Date:  2016-08-06

Review 10.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.